Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC

CAMBRIDGE - Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced updated...

Related Keywords

Massachusetts ,United States ,Boston ,Cambridge ,Cambridgeshire ,United Kingdom ,Jessicaj Lin ,Christopher Turner ,James Porter ,Chelcie Lister ,Exchange Commission ,Nuvalent Inc ,Cancer Center ,Nasdaq ,Harvard Medical School ,Assistant Professor ,Medical School ,Attending Physician ,General Cancer ,Chief Medical Officer ,Chief Executive Officer ,Human Preliminary Phase ,Private Securities Litigation Reform Act ,Risk Factor ,Quarterly Report ,News Publishing ,Markets ,